Tilray Shares Face Intensified Sell-Off Pressure

Critical Financial Metrics Under Scrutiny

Tilray’s stock is confronting severe market headwinds as analyst sentiment deteriorates dramatically. The cannabis company’s rating has been downgraded from “Sell” to “Strong Sell,” accelerating its downward trajectory. Market experts point to concerning valuation levels following recent price appreciation and highlight the troubling increase in outstanding shares. The security now battles to maintain its position above the critical $1 threshold.

All eyes turn to October 9th, when Tilray will disclose first-quarter results for fiscal year 2026. Expectations remain subdued, with researchers projecting modest revenue growth of 3% to $205.8 million. This figure represents a substantial sequential decline from previous performance.